PE20120833A1 - Compuestos sustituidos de espiro-amida - Google Patents
Compuestos sustituidos de espiro-amidaInfo
- Publication number
- PE20120833A1 PE20120833A1 PE2011001692A PE2011001692A PE20120833A1 PE 20120833 A1 PE20120833 A1 PE 20120833A1 PE 2011001692 A PE2011001692 A PE 2011001692A PE 2011001692 A PE2011001692 A PE 2011001692A PE 20120833 A1 PE20120833 A1 PE 20120833A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- dihydro
- spiro
- compounds
- diazaespiro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- -1 DECANE-3-CARBONYL Chemical class 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ESPIRO-AMIDA SUSTITUIDO DE FORMULA (I) DONDE a ES 0 A 1; b ES DE 0 A 2; t ES DE 1 A 3; c, d, e Y f SON CADA UNO DE 0 A 2; D ES UNO DE LOS RADICALES D1 O D2, EN DONDE q Y s SON CADA UNO 0 O 1; r ES DE 1 A 3; B ES C(=O), S(=O)2, ENTRE OTROS; Q1 Y Q2 SON CADA UNO C, CH O N; R1 ES ALQUILO(C1-C6), ARILO, HETEROARILO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; R3 Y R4 JUNTO CON -Q1-Q2- FORMAN UN ANILLO DE 4 A 7 MIEMBROS; R5 ES F, Cl, CF3, OCF3, OH, ENTRE OTROS; R6 ES F, CF3, ALQUILO(C1-C6), NO2, ENTRE OTROS; R7 Y R8 SON CADA UNO F, OH, =O, ALQUILO(C1-C6), ENTRE OTROS; X ES O, NR11, ENTRE OTROS; Y ES O, NR13, ENTRE OTROS, EN DONDE R11 Y R13 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; Z ES O, NR15, ENTRE OTROS, EN DONDE R15 ES H, ALQUILO(C1-C10), ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 7-CLORO-2-[6-(9-PIRIDIN-4-IL-3,9-DIAZAESPIRO[5.5]UNDECANO-3-CARBONIL)-2,3-DIHIDRO-1H-INDEN-1-IL]-2,3-DIHIDRO-ISOINDOL-1-ONA; N-[6-[9-(AZETIDIN-1-IL)-3-AZAESPIRO[5.5]UNDECANO-3-CARBONIL]-2,3-DIHIDRO-1H-INDEN-1-IL]-2-CLORO-BENZAMIDA; 7-CLORO-2-[(1S)-7-(8-PIRIDIN-4-IL-3,8-DIAZAESPIRO[4.5]DECANO-3-CARBONIL)-1,2,3,4-TETRAHIDRO-NAFTALINA-1-IL]-2,3-DIHIDRO-ISOINDOL-1-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE LA BRADIQUININA 1 (B1R) SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR AGUDO, MIGRANA, DIABETES, OBESIDAD
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09004235 | 2009-03-25 | ||
EP09011708 | 2009-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120833A1 true PE20120833A1 (es) | 2012-07-23 |
Family
ID=42224836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001692A PE20120833A1 (es) | 2009-03-25 | 2010-03-23 | Compuestos sustituidos de espiro-amida |
Country Status (19)
Country | Link |
---|---|
US (2) | US8455475B2 (es) |
EP (1) | EP2411381A1 (es) |
JP (1) | JP2012521377A (es) |
KR (1) | KR20110137377A (es) |
CN (1) | CN102365276A (es) |
AR (1) | AR076148A1 (es) |
AU (1) | AU2010227802A1 (es) |
BR (1) | BRPI1013614A2 (es) |
CA (1) | CA2756532A1 (es) |
CO (1) | CO6430424A2 (es) |
EC (1) | ECSP11011390A (es) |
IL (1) | IL215267A0 (es) |
MX (1) | MX2011010068A (es) |
NZ (1) | NZ595293A (es) |
PE (1) | PE20120833A1 (es) |
RU (1) | RU2011142618A (es) |
TW (1) | TW201038572A (es) |
WO (1) | WO2010108651A1 (es) |
ZA (1) | ZA201107772B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2623101B1 (en) | 2009-04-02 | 2021-04-21 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
EP2547679B1 (en) * | 2010-03-19 | 2015-11-04 | Pfizer Inc | 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
AR092645A1 (es) | 2012-09-25 | 2015-04-29 | Hoffmann La Roche | Derivados biciclicos inhibidores de autotaxina (atx) |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
PE20160661A1 (es) | 2013-09-12 | 2016-08-05 | Alios Biopharma Inc | Compuesto de azapiridona y sus usos de los mismos |
CN105764905B (zh) | 2013-11-26 | 2019-06-07 | 豪夫迈·罗氏有限公司 | 新的八氢-环丁二烯并[1,2-c;3,4-c’]二吡咯-2基 |
EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
PL3122750T3 (pl) | 2014-03-26 | 2020-03-31 | F.Hoffmann-La Roche Ag | Związki bicykliczne jako inhibitory wytwarzania autotaksyny (ATX) i kwasu lizofosfatydowego (LPA) |
WO2016008582A1 (en) * | 2014-07-15 | 2016-01-21 | Grünenthal GmbH | Substituted azaspiro(4.5)decane derivatives |
EP3268368A4 (en) | 2015-03-11 | 2018-11-14 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
CN106008503B (zh) * | 2015-03-31 | 2020-09-01 | 齐鲁制药有限公司 | 螺环芳基砜作为蛋白激酶抑制剂 |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
MX2018000511A (es) | 2015-09-04 | 2018-04-24 | Hoffmann La Roche | Derivados de fenoximetilo. |
AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
CR20180143A (es) | 2015-09-24 | 2018-05-03 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca |
MA42923A (fr) | 2015-09-24 | 2021-04-28 | Hoffmann La Roche | Composés bicycliques comme inhibiteurs mixtes de atx/ca |
EP3353180B1 (en) | 2015-09-24 | 2022-03-16 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
WO2017072341A1 (en) | 2015-10-30 | 2017-05-04 | F. Hoffmann-La Roche Ag | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
CA3005945A1 (en) * | 2015-12-22 | 2017-06-29 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
TWI640514B (zh) | 2016-01-13 | 2018-11-11 | 歌林達有限公司 | 3-(羧甲基)-8-胺基-2-側氧基-1,3-二氮-螺-[4.5]-癸烷衍生物 |
EA037598B1 (ru) | 2016-01-13 | 2021-04-20 | Грюненталь Гмбх | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана |
RS60855B1 (sr) | 2016-01-13 | 2020-10-30 | Gruenenthal Gmbh | Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
CN114539284A (zh) | 2016-03-16 | 2022-05-27 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
WO2018023029A1 (en) * | 2016-07-28 | 2018-02-01 | Mayo Foundation For Medical Education And Research | Small molecule activators of parkin enzyme function |
EP3366683A1 (en) * | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
CA3053329A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as dual atx/ca inhibitors |
JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ.ホフマン-ラ ロシュ アーゲー | Atxインヒビターとしての新規二環式化合物 |
EP3684361A4 (en) * | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE |
WO2019200114A1 (en) * | 2018-04-12 | 2019-10-17 | Arbutus Biopharma Corporation | Methods for preparing substituted dihydroindene-4-carboxamide compounds |
CN111434664A (zh) * | 2019-01-13 | 2020-07-21 | 西南大学 | 亚胺螺环哌啶类化合物的合成及应用 |
CN113976072B (zh) * | 2021-11-10 | 2024-02-23 | 武汉青风凯默生物医药科技有限公司 | 一种4-甲酰基-n-cbz哌啶的制备装置及方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1109544A4 (en) * | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE |
DE60033071T2 (de) * | 1999-12-06 | 2007-08-23 | Euro-Celtique S.A. | Triazospiroverbindungen mit nociceptin-rezeptoraffinität |
JP2007528420A (ja) | 2004-03-11 | 2007-10-11 | グラクソ グループ リミテッド | 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト |
US7468371B2 (en) | 2004-03-24 | 2008-12-23 | Abbott Laboratories Inc. | Tricyclic pyrazole kinase inhibitors |
CN101080389A (zh) * | 2004-10-15 | 2007-11-28 | 拜尔药品公司 | 具有抗增殖活性的茚满酰胺 |
CN101103016A (zh) * | 2004-11-18 | 2008-01-09 | 因塞特公司 | 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法 |
EP1877401A2 (en) * | 2005-04-15 | 2008-01-16 | Elan Pharmaceuticals Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
DE102005030051A1 (de) * | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
ATE509023T1 (de) * | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
WO2007140383A2 (en) * | 2006-05-30 | 2007-12-06 | Neurogen Corporation | Spirocyclic sulfonamides and related compounds |
DK2066659T3 (da) | 2006-09-29 | 2013-12-09 | Gruenenthal Gmbh | Substitueret sulfonamid-derivat |
EP2086935A1 (de) | 2006-10-16 | 2009-08-12 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
-
2010
- 2010-03-19 TW TW099108105A patent/TW201038572A/zh unknown
- 2010-03-23 JP JP2012501179A patent/JP2012521377A/ja active Pending
- 2010-03-23 MX MX2011010068A patent/MX2011010068A/es active IP Right Grant
- 2010-03-23 AU AU2010227802A patent/AU2010227802A1/en not_active Abandoned
- 2010-03-23 KR KR1020117025143A patent/KR20110137377A/ko not_active Application Discontinuation
- 2010-03-23 EP EP10711343A patent/EP2411381A1/en not_active Withdrawn
- 2010-03-23 NZ NZ595293A patent/NZ595293A/xx not_active IP Right Cessation
- 2010-03-23 RU RU2011142618/04A patent/RU2011142618A/ru not_active Application Discontinuation
- 2010-03-23 WO PCT/EP2010/001804 patent/WO2010108651A1/en active Application Filing
- 2010-03-23 CN CN2010800139828A patent/CN102365276A/zh active Pending
- 2010-03-23 BR BRPI1013614A patent/BRPI1013614A2/pt not_active IP Right Cessation
- 2010-03-23 CA CA2756532A patent/CA2756532A1/en not_active Abandoned
- 2010-03-23 PE PE2011001692A patent/PE20120833A1/es not_active Application Discontinuation
- 2010-03-24 US US12/730,597 patent/US8455475B2/en not_active Expired - Fee Related
- 2010-03-25 AR ARP100100948A patent/AR076148A1/es not_active Application Discontinuation
-
2011
- 2011-09-21 IL IL215267A patent/IL215267A0/en unknown
- 2011-09-22 CO CO11123935A patent/CO6430424A2/es not_active Application Discontinuation
- 2011-10-11 EC ECSP11011390 patent/ECSP11011390A/es unknown
- 2011-10-24 ZA ZA2011/07772A patent/ZA201107772B/en unknown
-
2013
- 2013-04-15 US US13/862,690 patent/US20130231327A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8455475B2 (en) | 2013-06-04 |
CN102365276A (zh) | 2012-02-29 |
BRPI1013614A2 (pt) | 2019-09-24 |
JP2012521377A (ja) | 2012-09-13 |
CO6430424A2 (es) | 2012-04-30 |
NZ595293A (en) | 2012-10-26 |
WO2010108651A1 (en) | 2010-09-30 |
IL215267A0 (en) | 2011-11-30 |
AR076148A1 (es) | 2011-05-18 |
KR20110137377A (ko) | 2011-12-22 |
MX2011010068A (es) | 2011-10-06 |
ZA201107772B (en) | 2012-07-25 |
TW201038572A (en) | 2010-11-01 |
RU2011142618A (ru) | 2013-04-27 |
EP2411381A1 (en) | 2012-02-01 |
US20100249095A1 (en) | 2010-09-30 |
AU2010227802A1 (en) | 2011-11-10 |
ECSP11011390A (es) | 2012-03-30 |
CA2756532A1 (en) | 2010-09-30 |
US20130231327A1 (en) | 2013-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120833A1 (es) | Compuestos sustituidos de espiro-amida | |
PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
PE20071023A1 (es) | Azaciclilaminas-n-sustituidas como antagonistas de histamina-3 | |
PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20161443A1 (es) | Compuestos | |
PE20100718A1 (es) | Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas | |
PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
PE20140927A1 (es) | Compuestos heterociclicos como inhibidores de cinasas | |
PE20110196A1 (es) | 5-alquinil-pirimidinas | |
PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
PE20121639A1 (es) | Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 | |
PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
PE20080371A1 (es) | N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3 | |
PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
ATE493404T1 (de) | Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |